JP7197474B2 - 分散性組成物 - Google Patents

分散性組成物 Download PDF

Info

Publication number
JP7197474B2
JP7197474B2 JP2019521720A JP2019521720A JP7197474B2 JP 7197474 B2 JP7197474 B2 JP 7197474B2 JP 2019521720 A JP2019521720 A JP 2019521720A JP 2019521720 A JP2019521720 A JP 2019521720A JP 7197474 B2 JP7197474 B2 JP 7197474B2
Authority
JP
Japan
Prior art keywords
composition
fraction
excipient
peg
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019521720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500168A (ja
JP2020500168A5 (enExample
Inventor
パタンカー，ハーシャド
ゴイヴァイェルツ，ニコラース，マルサ，フェリックス
ラジャン，ゴパル ラジャン ランガ
Original Assignee
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー filed Critical ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー
Publication of JP2020500168A publication Critical patent/JP2020500168A/ja
Publication of JP2020500168A5 publication Critical patent/JP2020500168A5/ja
Priority to JP2022165319A priority Critical patent/JP2023011659A/ja
Application granted granted Critical
Publication of JP7197474B2 publication Critical patent/JP7197474B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019521720A 2016-10-24 2017-10-23 分散性組成物 Active JP7197474B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022165319A JP2023011659A (ja) 2016-10-24 2022-10-14 分散性組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201621036404 2016-10-24
IN201621036404 2016-10-24
PCT/EP2017/077030 WO2018077815A1 (en) 2016-10-24 2017-10-23 Dispersible compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022165319A Division JP2023011659A (ja) 2016-10-24 2022-10-14 分散性組成物

Publications (3)

Publication Number Publication Date
JP2020500168A JP2020500168A (ja) 2020-01-09
JP2020500168A5 JP2020500168A5 (enExample) 2020-12-10
JP7197474B2 true JP7197474B2 (ja) 2022-12-27

Family

ID=60262899

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019521720A Active JP7197474B2 (ja) 2016-10-24 2017-10-23 分散性組成物
JP2022165319A Withdrawn JP2023011659A (ja) 2016-10-24 2022-10-14 分散性組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022165319A Withdrawn JP2023011659A (ja) 2016-10-24 2022-10-14 分散性組成物

Country Status (21)

Country Link
US (2) US11065198B2 (enExample)
EP (2) EP3528791B1 (enExample)
JP (2) JP7197474B2 (enExample)
KR (2) KR20190073450A (enExample)
CN (1) CN110191704A (enExample)
CA (1) CA3039562A1 (enExample)
DK (1) DK3528791T3 (enExample)
ES (1) ES2970870T3 (enExample)
FI (1) FI3528791T3 (enExample)
HR (1) HRP20240118T1 (enExample)
HU (1) HUE064823T2 (enExample)
LT (1) LT3528791T (enExample)
MA (1) MA46563B1 (enExample)
MX (1) MX2019004767A (enExample)
PL (1) PL3528791T3 (enExample)
PT (1) PT3528791T (enExample)
RS (1) RS65159B1 (enExample)
SI (1) SI3528791T1 (enExample)
SM (1) SMT202400060T1 (enExample)
TW (1) TWI821163B (enExample)
WO (1) WO2018077815A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA56449A (fr) * 2019-07-03 2022-05-11 Janssen Sciences Ireland Unlimited Co Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine
WO2021104487A1 (en) 2019-11-29 2021-06-03 Aptorum Therapeutics Limited Composition including rilpivirine and use thereof for treating tumors or cancer
WO2021253380A1 (en) * 2020-06-19 2021-12-23 InventisBio Co., Ltd. Oral formulations and uses thereof
CN114392241B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种利匹韦林片及其制备方法
GB202211231D0 (en) * 2022-08-02 2022-09-14 Glaxosmithkline Ip No 2 Ltd Novel formulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008511592A (ja) 2004-09-02 2008-04-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ４−［［４−［［４−（２−シアノエテニル）−２，６−ジメチルフェニル］アミノ］−２−ピリミジニル］アミノ］ベンゾニトリルの塩酸塩
WO2015136294A1 (en) 2014-03-13 2015-09-17 Cipla Limited Pharmaceutical composittion comprising rilpivirine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181966A1 (en) * 1984-11-13 1986-05-28 Gist-Brocades N.V. Compression-coated dispersible tablets
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7399856B2 (en) 2002-08-09 2008-07-15 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-2pyrimidinyl]amino]benzonitrile
SG155885A1 (en) * 2004-09-02 2009-10-29 Janssen Pharmaceutica Nv Furamate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2- pyrimidinyl)amino)benzonitrile
CA2577288C (en) 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
PT3366278T (pt) 2006-06-23 2024-10-21 Janssen Sciences Ireland Unlimited Co Suspensões aquosas de tmc278
EP3102188A4 (en) * 2014-02-05 2017-07-12 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
AU2015258836B2 (en) * 2014-05-16 2020-07-16 Vivus, Inc. Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008511592A (ja) 2004-09-02 2008-04-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ４−［［４−［［４−（２−シアノエテニル）−２，６−ジメチルフェニル］アミノ］−２−ピリミジニル］アミノ］ベンゾニトリルの塩酸塩
WO2015136294A1 (en) 2014-03-13 2015-09-17 Cipla Limited Pharmaceutical composittion comprising rilpivirine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHRISTINE ELIZABETH STRACHAN，THE FORMULATION TECHNOLOGY OF DISPERSIBLE TABLETS.，A thesis submitted in partial fulfilment of the requirements of Liverpool John Moores University for degree of Doctor of Philosophy，2000年02月
CRAUWELS, Herta et al.，Relative bioavailability and food effect of a paediatric dispersible tablet formulation of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV)，Journal of the International AIDS Society, Abstracts of the HIV Glasgow supplement，2016年10月23日，19 (Suppl 7)，p. 39，P032
NCT02561936, ClinicalTrials.gov [online]，2016年06月10日，[令和3年7月17日検索]、インターネット ＜URL：https://clinicaltrials.gov/ct2/show/NCT02561936?term=NCT02561936&draw=2&rank=1＞

Also Published As

Publication number Publication date
TWI821163B (zh) 2023-11-11
US20220008333A1 (en) 2022-01-13
MA46563A (fr) 2019-08-28
RU2019115672A (ru) 2020-11-24
RS65159B1 (sr) 2024-02-29
SI3528791T1 (sl) 2024-04-30
TW201828927A (zh) 2018-08-16
KR102861006B1 (ko) 2025-09-16
US11065198B2 (en) 2021-07-20
EP3528791B1 (en) 2023-12-06
ES2970870T3 (es) 2024-05-31
JP2020500168A (ja) 2020-01-09
SMT202400060T1 (it) 2024-03-13
PT3528791T (pt) 2024-02-19
EP4248947A2 (en) 2023-09-27
JP2023011659A (ja) 2023-01-24
MA46563B1 (fr) 2024-01-31
MX2019004767A (es) 2019-07-01
EP4248947A3 (en) 2023-11-22
CA3039562A1 (en) 2018-05-03
HRP20240118T1 (hr) 2024-04-12
KR20190073450A (ko) 2019-06-26
US20200069579A1 (en) 2020-03-05
LT3528791T (lt) 2024-05-27
BR112019007564A2 (pt) 2019-07-02
PL3528791T3 (pl) 2024-04-02
EP3528791A1 (en) 2019-08-28
WO2018077815A1 (en) 2018-05-03
HUE064823T2 (hu) 2024-04-28
RU2019115672A3 (enExample) 2021-01-21
DK3528791T3 (da) 2024-01-29
CN110191704A (zh) 2019-08-30
KR20240011873A (ko) 2024-01-26
FI3528791T3 (fi) 2024-01-30

Similar Documents

Publication Publication Date Title
AU2021204135B2 (en) Dispersible compositions
JP2023011659A (ja) 分散性組成物
RS51923B2 (sr) So 4[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2- pirimidinil]amino]benzonitrila
HK40101645A (en) Dispersible compositions
RU2826218C2 (ru) Диспергируемые композиции
HK40013979A (en) Dispersible compositions
HK40013979B (en) Dispersible compositions
CN101068597B (zh) 4-((4-((4-(2-氰基乙烯基)-2,6-二甲基苯基)氨基)-2-嘧啶基)氨基)苄腈的富马酸盐
BR112019007564B1 (pt) Composições dispersíveis, seu processo de fabricação e uso de rilpivirina
HK40013937A (en) Dispersible compositions
CA2973301C (en) Dispersible compositions comprising bedaquiline fumarate
HK40069676A (en) Dispersible compositions
OA18325A (en) Dispersible compositions
EA042247B1 (ru) Диспергируемые композиции
HK1112862B (en) Furamate of 4-((4-(4-(2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201028

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221014

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221014

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221020

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221025

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221215

R150 Certificate of patent or registration of utility model

Ref document number: 7197474

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250